Price Chart

Profile

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
URL https://www.modernatx.com
Investor Relations URL https://investors.modernatx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 22, 2024
Last Earnings Release Feb. 22, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
URL https://www.modernatx.com
Investor Relations URL https://investors.modernatx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 22, 2024
Last Earnings Release Feb. 22, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A